Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
According to Quoin Pharmaceuticals, Ltd.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.00. At the end of 2022 the company had a P/S ratio of 0.00.
Year | P/S ratio |
---|---|
2023 | 0.00 |
2022 | 0.00 |
2021 | 0.00 |
2020 | 0.00 |
2019 | 0.00 |
2018 | -48.53 |
2017 | 0.00 |
2016 | -50.28 |
2015 | 0.00 |